NBTY Cuts Its Losses, Leaving Contract Manufacturing
This article was originally published in The Tan Sheet
Executive Summary
The supplement manufacturer and retailer says it will cease contract manufacturing as it increases its focus on growing its branded product and retail businesses, particularly internationally. Private label production continues but will become a smaller part of its business.
You may also be interested in...
Nature's Bounty Returns To Top Billing As NBTY's New Name
The firm owned since 2010 by a Carlyle Group holding company opts for a name that encompasses its largest brand, which also had been its name until the previous management chose the name NBTY in 1995.
NBTY Targets Unleashing Growth From Private Label Drag
“Where we have opportunities to hold on to” private label business, “we'll hold on to it, but not at any cost,” says President and CEO Steve Cahillane. “Due to private label margins” becomes common refrain in NBTY’s income downturn.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”